Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received…
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)…
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -…
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a…
-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median…
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung…
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab…
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:…